201 related articles for article (PubMed ID: 10949204)
1. Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension.
Schroeder RA; Rafii AA; Plotkin JS; Johnson LB; Rustgi VK; Kuo PC
Transplantation; 2000 Aug; 70(3):548-50. PubMed ID: 10949204
[TBL] [Abstract][Full Text] [Related]
2. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension.
Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W
Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327
[TBL] [Abstract][Full Text] [Related]
3. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension.
Plotkin JS; Kuo PC; Rubin LJ; Gaine S; Howell CD; Laurin J; Njoku MJ; Lim JW; Johnson LB
Transplantation; 1998 Feb; 65(4):457-9. PubMed ID: 9500616
[TBL] [Abstract][Full Text] [Related]
4. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension.
Kuo PC; Johnson LB; Plotkin JS; Howell CD; Bartlett ST; Rubin LJ
Transplantation; 1997 Feb; 63(4):604-6. PubMed ID: 9047158
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis.
Parameswaran K; Purcell I; Farrer M; Holland C; Taylor IK; Keaney NP
Respir Med; 1999 Feb; 93(2):75-8. PubMed ID: 10464856
[TBL] [Abstract][Full Text] [Related]
6. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol.
Rafanan AL; Maurer J; Mehta AC; Schilz R
Chest; 2000 Nov; 118(5):1497-500. PubMed ID: 11083710
[TBL] [Abstract][Full Text] [Related]
7. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol.
Ramsay MA; Spikes C; East CA; Lynch K; Hein HA; Ramsay KJ; Klintmalm GB
Anesthesiology; 1999 Jan; 90(1):299-301. PubMed ID: 9915339
[No Abstract] [Full Text] [Related]
8. [Portopulmonary hypertension].
Halank M; Miehlke S; Kolditz M; Hoeffken G
Z Gastroenterol; 2005 Jul; 43(7):677-85. PubMed ID: 16001350
[TBL] [Abstract][Full Text] [Related]
9. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation.
Kett DH; Acosta RC; Campos MA; Rodriguez MJ; Quartin AA; Schein RM
Liver Transpl; 2001 Jul; 7(7):645-8. PubMed ID: 11460234
[TBL] [Abstract][Full Text] [Related]
10. Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension.
Schenk P; Petkov V; Madl C; Kramer L; Kneussl M; Ziesche R; Lang I
Chest; 2001 Jan; 119(1):296-300. PubMed ID: 11157622
[TBL] [Abstract][Full Text] [Related]
11. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.
Olschewski H; Walmrath D; Schermuly R; Ghofrani A; Grimminger F; Seeger W
Ann Intern Med; 1996 May; 124(9):820-4. PubMed ID: 8610951
[TBL] [Abstract][Full Text] [Related]
12. Effect of aerosolized prostacyclin and inhaled nitric oxide on experimental hypoxic pulmonary hypertension.
Max M; Kuhlen R; Dembinski R; Rossaint R
Intensive Care Med; 1999 Oct; 25(10):1147-54. PubMed ID: 10551974
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol.
Fix OK; Bass NM; De Marco T; Merriman RB
Liver Transpl; 2007 Jun; 13(6):875-85. PubMed ID: 17539008
[TBL] [Abstract][Full Text] [Related]
14. Moderate-term effect of epoprostenol on severe portopulmonary hypertension.
Kato H; Katori T; Nakamura Y; Kawarasaki H
Pediatr Cardiol; 2003; 24(1):50-3. PubMed ID: 12574979
[TBL] [Abstract][Full Text] [Related]
15. Successful Liver Transplant Complicated by Severe Portopulmonary Hypertension After an Initial Aborted Attempt: Case Report and Review of Treatment Options.
Reid K; McQuillan P; Kadry Z; Janicki P; Bezinover D
Exp Clin Transplant; 2017 Jun; 15(3):361-365. PubMed ID: 26101938
[TBL] [Abstract][Full Text] [Related]
16. Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension.
Hollatz TJ; Musat A; Westphal S; Decker C; D'Alessandro AM; Keevil J; Zhanhai L; Runo JR
Liver Transpl; 2012 Jun; 18(6):686-95. PubMed ID: 22315210
[TBL] [Abstract][Full Text] [Related]
17. Long-term epoprostenol therapy in pulmonary artery hypertension.
Sakuma M; Demachi J; Nawata J; Suzuki J; Takahashi T; Shirato K
Circ J; 2009 Mar; 73(3):523-9. PubMed ID: 19179773
[TBL] [Abstract][Full Text] [Related]
18. [Epoprostenol in the treatment of portopulmonary hypertension].
Culafić D; Culafić-Vojinović V; Jesić R
Srp Arh Celok Lek; 2003; 131(5-6):271-4. PubMed ID: 14692137
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension.
Strange C; Bolster M; Mazur J; Taylor M; Gossage JR; Silver R
Chest; 2000 Oct; 118(4):1077-82. PubMed ID: 11035680
[TBL] [Abstract][Full Text] [Related]
20. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
